Results from laboratory experiments carried out by a team of molecular biologists at Saarland University have identified a strategy for overcoming resistance to a new therapeutic opportunity for prostate cancer patients and for potentially suppressing the migration of cancer cells.
The new therapeutic approach, which is currently being studied by numerous research groups, aims to destroy cancer cells by influencing cellular calcium distribution. However, the research team, supervised by Professor Richard Zimmermann and Dr Markus Greiner, found that in about half of the patients examined, a cellular mechanism was present that could impede the efficacy of the new therapy.
The molecular biologists discovered that this resistance was caused by an increased concentration of the protein Sec62 in the tumour cells. Results from their laboratory cell line experiments indicate that a pharmaceutically active agent previously used in the treatment of psychotic disorders can counteract the observed cellular resistance as well as supress cell migration. The research team has published its findings in the medical journal BMC Cancer.
Prostate cancer is the most common malignant tumour in men. A new therapeutic approach to combating the disease is currently the subject of international research. In recent years, US scientists have developed a number of analogues of thapsigargin that are capable of selectively killing tumour cells by emptying the calcium stores in these cells.
But recent research by scientists at Saarland University’s Faculty of Medicine in Homburg has demonstrated that in approximately half of the patients suffering from prostate cancer, the tumour cells can be expected to show a resistance to this new form of therapy.
‘The resistance mechanism is due to a higher concentration of the protein Sec62,’ explains Professor Richard Zimmermann. As a result of increased Sec62 levels the protein calmodulin can close the calcium leak channels more efficiently in the membrane of the important intracellular calcium store known as the endoplasmic reticulum. ‘This is why tumour cells with a higher concentration of Sec62 show greater resistance to treatment regimens based on thapsigargin analogues,’ says Zimmermann.
Working with tumour cell cultures in the laboratory, Zimmermann’s group at the Department of Medical Biochemistry and Molecular Biology has found a possible solution to the problem and their results have been published in the journal BMC Cancer. ‘Using tumour cell lines, we were able to show that a substance called trifluoperazine (TFP) was able to counteract the observed resistance. TFP has been used as an antipsychotic and was marketed in Germany under the brand Jatroneutral® where it was used in the treatment of psychotic disorders,’ explains Dr Markus Greiner, a member of Professor Zimmermann’s research team. ‘TFP binds directly to the protein calmodulin and thus impairs the calmodulin-mediated closure of the calcium channels,’ explains Greiner.
Sec62 has been shown to be an important tumour marker, i.e. a protein that occurs at enhanced concentrations in tumour cells, not only in prostate carcinomas, but also in thyroid and lung carcinomas. The Homburg researchers see a correlation between the presence of Sec62 protein and a more aggressive tumour and hence lower patient survival rates. The research team also measured increased Sec62 concentrations in tumours that had already metastasized.
‘Calcium is an important signalling molecule that regulates cell migration, which is itself an important contributor to tumour metastasis,’ says Markus Greiner. The calcium in the cells ensures that the cells can detect the direction in which they are migrating. If these tumour cells are treated with TFP, the calcium store will be emptied and the cells essentially lose their orientation. ‘This leads to an almost complete cessation of cellular migration,’ explains Greiner.
‘We propose a therapeutic approach based on TFP in combination with thapsigargin analogues. In future, this may be a therapeutic option for those many patients whose tumours have a high cellular concentration of Sec62, which might make them unsuitable for treatment with thapsigargin,’ says Greiner. The results obtained by the Homburg research team will now be evaluated in tumour model studies before any clinical trials can be proposed.
Original publication: Linxweiler M., Schorr S., Schäuble N., Jung M., Linxweiler J., Langer F., Schäfers H.-J., Cavaliè A., Zimmermann R., and Greiner M.: Targeting cell migration and Endoplasmic Reticulum stress response with calmodulin antagonists: Mimicking Sec62-depletion phenotypes by small molecule treatment, BMC Cancer, 2013, 13:574;
Contact: Prof. Dr. Richard Zimmermann: +49 (0)6841 162-6511
Dr. Markus Greiner: +49 (0)6841 162-6515 E-mail: email@example.com
Press photographs are available at http://www.uni-saarland.de/pressefotos and can be used free of charge.
Claudia Ehrlich | Universität des Saarlandes
Gene switch may repair DNA and prevent cancer
12.02.2016 | Institute for Integrated Cell-Material Sciences at Kyoto University
New method opens crystal clear views of biomolecules
11.02.2016 | Deutsches Elektronen-Synchrotron DESY
Today, plants and microorganisms are heavily used for the production of medicinal products. The production of biopharmaceuticals in plants, also referred to as “Molecular Pharming”, represents a continuously growing field of plant biotechnology. Preferred host organisms include yeast and crop plants, such as maize and potato – plants with high demands. With the help of a special algal strain, the research team of Prof. Ralph Bock at the Max Planck Institute of Molecular Plant Physiology in Potsdam strives to develop a more efficient and resource-saving system for the production of medicines and vaccines. They tested its practicality by synthesizing a component of a potential AIDS vaccine.
The use of plants and microorganisms to produce pharmaceuticals is nothing new. In 1982, bacteria were genetically modified to produce human insulin, a drug...
Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock which attains an accuracy which had only been predicted theoretically so far. Their optical ytterbium clock achieved a relative systematic measurement uncertainty of 3 E-18. The results have been published in the current issue of the scientific journal "Physical Review Letters".
Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock...
The University of Würzburg has two new space projects in the pipeline which are concerned with the observation of planets and autonomous fault correction aboard satellites. The German Federal Ministry of Economic Affairs and Energy funds the projects with around 1.6 million euros.
Detecting tornadoes that sweep across Mars. Discovering meteors that fall to Earth. Investigating strange lightning that flashes from Earth's atmosphere into...
Physicists from Saarland University and the ESPCI in Paris have shown how liquids on solid surfaces can be made to slide over the surface a bit like a bobsleigh on ice. The key is to apply a coating at the boundary between the liquid and the surface that induces the liquid to slip. This results in an increase in the average flow velocity of the liquid and its throughput. This was demonstrated by studying the behaviour of droplets on surfaces with different coatings as they evolved into the equilibrium state. The results could prove useful in optimizing industrial processes, such as the extrusion of plastics.
The study has been published in the respected academic journal PNAS (Proceedings of the National Academy of Sciences of the United States of America).
Exceeding critical temperature limits in the Southern Ocean may cause the collapse of ice sheets and a sharp rise in sea levels
A future warming of the Southern Ocean caused by rising greenhouse gas concentrations in the atmosphere may severely disrupt the stability of the West...
12.02.2016 | Event News
09.02.2016 | Event News
02.02.2016 | Event News
12.02.2016 | Physics and Astronomy
12.02.2016 | Life Sciences
12.02.2016 | Medical Engineering